The buoyant densities of human erythrocytes with normal (HbAA) and abnormal heterozygous haemoglobins (HbSS, HbAS, HbSC) as well as erythrocytes from guinea pig and pigeon were determined by centrifugation in discontinuous density gradients of metrizamide. Guinea pig, pigeon and human erythrocytes from normal human adult (HbAA) and from heterozygote HbAS were found to have the same density of 1.1381 g/cm3, while erythrocytes from a sickle-cell patient (HbS) and from a heterozygote HbSC, HbSS and HbSC, which are known to have a higher lipid content than isovolumic normal cells, had a lower density of 1.1261 g/cm3. When centrifugation was carried out under non-equilibrium conditions (rate zonal), several sedimentation bands were obtained from each erythrocyte preparation. Differences in the sedimentation rates were unrelated to the haemoglobin composition of the erythrocytes. It is suggested that the lower density of the erythrocytes associated with sickle-cell disease may have significant consequences in the circulation of such cells and in the clinical sequence of the sickling process.

Keywords:
Isopycnic centrifugation, Human haemoglobin genotypes, Sickle-cell erythrocytes
This content is only available via PDF.
© 1980 S. Karger AG, Basel
1980
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.